Fluvac Innovator®

Fluvac Innovator EHV-4/1 provides your horse with trusted protection against equine influenza and equine herpesvirus,1 and is the perfect pair to Core EQ Innovator.

The importance of protecting against respiratory disease

Respiratory diseases such as equine influenza (flu) and equine herpesvirus (rhino) are classified as risk-based by the American Association of Equine Practitioners (AAEP) because their likelihood of occurrence depends on factors like travel or cohabitation with traveling horses.2 Due to their high contagiousness, flu and rhino are the top risk-based vaccinations recommended for horses. Among risk-based diseases, respiratory disease is the primary cause of horse death, with equine flu and herpesvirus being the main respiratory illnesses.2

    Equine Influenza (Flu)

    Equine Herpesvirus (Rhino)

    The benefits of Fluvac Innovator®

    Fluvac Innovator EHV-4/1 provides trusted protection against the risks of equine influenza (flu) and herpesvirus (rhino). Plus, research has shown that dividing core and risk-based vaccines into separate injections provided up to 4.7 times the immune response against equine influenza than combination vaccines that included equine influenza protection.3

    The #1 most trusted equine respiratory vaccine in the United States1
    Up to 4.7x better immune response against equine influenza3
    Since 2018, Fluvac Innovator has been successfully evaluated against 80 equine influenza viruses from 34 locations4-9
    Oil-in-water adjuvants, such as MetaStim®, were shown to promote cross-protective immunity against influenza strains in both humans and animals.10

    Choose Fluvac Innovator® EHV-4/1 with confidence

    Fluvac Innovator EHV-4/1 has been successfully tested against 80 equine influenza viruses (EIV) from 34 locations, including Canada and Europe, since 2018.4-9

    2017-2022 EIV isolates
    2017-2022 EIV isolates

    When should I vaccinate my horse?

    By splitting core from risk-based vaccines, your horse gets a customized vaccination program to help protect against the diseases that are most likely to be a threat. Learn more about vaccinating your horse for the five core equine diseases with Core EQ Innovator. Below is a vaccination schedule for protection from the core diseases and risk-based respiratory diseases aligned to the AAEP guidelines.2

    DiseasesAdult HorsesFoalsBroodmares
    Core Diseases: 
    Rabies
    Tetanus
    West Nile Virus (WNV)
    Eastern Equine Encephalomyelitis (EEE)
    Western Equine Encephalomyelitis (WEE)
    Annual revaccination:
    Recommended in spring
    First vaccination at 4 to 6-months of age

    Second dose 4-6 weeks after the first dose

    Booster at 10-12 months of age and annually thereafter
    Annual revaccination and administer 4-6 weeks pre-partum

    Core EQ Innovator is the first and only vaccine that includes protection against all five core diseases and has been demonstrated safe for use in broodmares during the third trimester.8
     
    Risk-based Respiratory Diseases:
    Equine Influenza Virus (EIV)
    Equine Herpesvirus (EHV-1 and EHV-4)
    Annual revaccination:
    Recommended in spring

    Horses at increased risk of exposure may receive booster every 6 months
    First vaccination at 4 to 6-months of age

    Second dose 3-4 weeks after first dose 

    Booster 10-12 months following the first dose and annually thereafter

    Horses at increased risk of exposure may receive booster every 6 months
    Annual revaccination and administer 4-6 weeks pre-partum

    Broodmares with ongoing risk of exposure should be boostered every 6 months
     
    In addition, other risk-based diseases may also pose a threat to your horse based on his unique needs and circumstances. Your veterinarian can provide guidance on which additional vaccines from the Zoetis portfolio may be appropriate for your horse’s vaccination schedule. See the vaccination guides below for adult horses, broodmares and foals for recommendations on what Zoetis vaccines may be appropriate for your horse’s unique needs.

    What sets Zoetis Innovator vaccines apart?

    MetaStim® adjuvant

    Only Zoetis Innovator vaccines are optimized with the MetaStim® adjuvant, designed to make presenting antigens into your horse’s immune system safe and effective, leading to an improved immune response.13,14

    Microfiltered 5x

    Zoetis Innovator vaccines are microfiltered five times to remove excess proteins that could lead to increased reactivity, resulting in greater antigen purity.

    Zoetis Vaccine Support Program

    When you protect your horse with Core EQ Innovator and Fluvac Innovator EHV-4/1 vaccines, you are also protected with one of the industry’s best Equine Immunization Support Guarantees. This reimburses up to $5,000 for documented diagnostic and treatment costs if a veterinarian properly administers one of these vaccines and the horse later contracts the corresponding disease. For complete details and requirements, see the see the Zoetis Equine Immunization Support Guarantee certificate.

    Extended portfolio of Zoetis vaccines

    Vaccinating against the five potentially fatal core equine diseases, plus any risk-based diseases based on your horse’s age, location and lifestyle, is the key to proactive protection. Together with your veterinarian, our safe and effective industry-leading vaccines have your horse’s back.

    CORE

    Multiple Diseases

    Ask a Vet

    The first and only vaccine to help protect against the five potentially fatal core equine diseases in a single injection.15

    CORE

    West Nile Virus

    Ask a Vet

    This line of vaccines aids in the prevention of West Nile, equine encephalomyelitis due to Eastern, Western and Venezuelan viruses, and tetanus. In a study, it was demonstrated to be 96.7% effective in immunologically naive horses.16

    RISK-BASED

    Strangles

    Ask a Vet

    Pinnacle® I.N.

    (modified-live streptococcus equi)

    Helps protect horses against strangles, the only modified-live bacterial vaccine developed to help prevent strangles caused by Streptococcus equi.

    RISK-BASED

    Herpesvirus Type 1

    Ask a Vet

    Pneumabort-K® + 1b

    (killed equine herpesvirus type 1 vaccine)

    The only equine vaccine labeled for use in pregnant mares to aid in the prevention of abortion due to equine herpes virus type 1 (EHV-1) infections and to help prevent respiratory infections cause by EHV-1p and EHV-1b.17-20

    RISK-BASED

    Equine Rotavirus

    Ask a Vet

    For the vaccination of pregnant mares to provide passive transfer of antibodies to foals against equine rotavirus, a viral diarrhea.

    *This product is conditionally licensed by the USDA while additional efficacy and potency data are being developed.

    RISK-BASED

    Equine Leptospirosis

    Ask a Vet

    Lepto EQ Innovator®

    (leptospira pomona bacterin)

    The first and only equine vaccine to help prevent leptospirosis in horses which may cause abortion, equine recurrent uvetitis, or renal disease.

    RISK-BASED

    Equine Arteritis

    Ask a Vet

    Arvac®

    (equine arteritis vaccine)

    Shown to be effective for the vaccination of healthy non-stressed adult horses as an aid in the prevention of viral abortion and respiratory infection due to equine arteritis virus.

    CORE

    Multiple Diseases

    Ask a Vet

    For the vaccination of healthy horses as an aid in the prevention of equine
    encephalomyelitis due to Eastern and Western viruses, and tetanus.

    References

    1. The Fluvac Innovator line had the most doses sold of all equine influenza vaccine lines on the market. Animalytix Segment Data, Equine Vaccines, MAT June 2023 (accessed June 20, 2023).
    2. American Association of Equine Practitioners. Vaccination Guidelines. https://aaep.org/guidelines/vaccination-guidelines. (Accessed January 22, 2023.) 
    3. Data on file, Study Report No. 14OREQBIO-1, Zoetis Inc. Data on file, Study Report No. 18EQRGBIO-01-02, Zoetis Inc.
    4. Data on file, Study Report No. 18EQRGBIO-01-02, Zoetis Inc. 
    5. Dilai M, et all. Serological investigation of racehorse vaccination against equine influenza in Morocco. Veterinary Microbiology. 223. 2018. 153-159.
    6. Data on file, Study Report No. 19EQRGBIO-01-02, Zoetis Inc. 
    7. Data on file, Study Report No. 21EQRGBIO-01-01, Zoetis Inc.
    8. Data on file, Study Report No. 22EQRGBIO-01-01, Zoetis Inc.
    9. Data on file, Study Report No. 23EQRGBIO-01-01, Zoetis Inc. 
    10. Vemula SV, Sayedahmed EE, Sambhara S, Mittal SK. Vaccine approaches conferring cross-protection against influenza viruses. Expert Rev Vaccines. 2017;16(11): 1141–1154.
    11. Landolt G, Hugh G, Townsend G, Lunn D. Equine influenza infection. In: Sellon D, Long M, eds. Equine Infectious Diseases, 1st edition. Philadelphia: WB Saunders, 2007;127. 
    12. Data on file. Study Report No. B951R-US-20-160, Zoetis Inc.
    13. Davis EG, Zhang Y, Tuttle J, Hankins K, Wilkerson M. Investigation of antigen specific lymphocyte responses in healthy horses vaccinated with an inactivated West Nile virus vaccine. Vet Immunol Immunopathol. 2008;126(3-4):293-301.
    14. Horohov DW, Dunham J, Liu C, et al. Characterization of the in situ immunological responses to vaccine adjuvants. Vet Immunol Immunopathol. 2015;164(1-2):24-29. 
    15. Data on file. Study Report No. B951R-US-20-160, Zoetis Inc.
    16. Epp T, Waldner C, Townsend HGG. A case-control study of factors associated with development of clinical disease due to West Nile virus, Saskatchewan 2003. Equine Vet J. 2007;39:498-503
    17. Bryans JT, Allen GP. Application of a chemically inactivated, adjuvanted vaccine to control abortigenic infection of mares by equine herpesvirus 1. Dev Biol Stand. 1982;52:493-498.
    18. Tengelsen LA, Yamini B, Mullaney TP, et al. A 12-year retrospective study of equine abortion in Michigan. J Vet Diagn Invest. 1997;9(3):303-306.
    19. Giles RC, Donahue JM, Hong CB, et al. Causes of abortion, stillbirth, and perinatal death in horses: 3,527 cases (1986-1991). J Am Vet Med Assoc. 1993;203(8):1170-1175.
    20. Hong CB, Donahue JM, Giles RC, et al. Equine abortion and stillbirth in central Kentucky during 1988 and 1989 foaling seasons. 
    21. J Vet Diagn Invest. 1993;5(4):560-566.